Baird has revised its price target for Dianthus (DNTH, Financial), reducing it from $58 to $50, while maintaining an Outperform rating on the stock. This adjustment follows the company's first-quarter results, which included updates to its product pipeline. The firm has factored these developments into its updated financial model for Dianthus. Investors are encouraged to stay informed about companies with stable fundamentals to navigate market uncertainties effectively.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Dianthus Therapeutics Inc (DNTH, Financial) is $49.11 with a high estimate of $58.00 and a low estimate of $36.00. The average target implies an upside of 144.58% from the current price of $20.08. More detailed estimate data can be found on the Dianthus Therapeutics Inc (DNTH) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Dianthus Therapeutics Inc's (DNTH, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
